Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZACHEL versus MENRIUM 5 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZACHEL versus MENRIUM 5 2.
CHLORDIAZACHEL vs MENRIUM 5-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.
Combination of chlordiazepoxide (benzodiazepine) potentiating GABA-A receptor activity, and clidinium (antimuscarinic) blocking muscarinic acetylcholine receptors.
Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.
1 tablet orally every 6-8 hours as needed for anxiety, up to 4 tablets per day. Each tablet contains chlordiazepoxide 5 mg and clidinium bromide 2.5 mg.
None Documented
None Documented
Parent: 5-30 hours (mean 15 hours); active metabolite desmethylchlordiazepoxide: 10-20 hours; further metabolite demoxepam: 24-96 hours; clinical context: causes drug accumulation with chronic dosing, especially in elderly or hepatic impairment.
Chlordiazepoxide: 5-30 hours (increases with age, hepatic impairment); Clidinium: 8-12 hours
Renal: 50-70% as metabolites (mainly oxazepam and desmethylchlordiazepoxide); biliary/fecal: 10-20% as glucuronide conjugates; 1-2% excreted unchanged.
Chlordiazepoxide: 90-96% renal as metabolites, <5% unchanged; Clidinium: 70-80% fecal, 10-20% renal as metabolites
Category C
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination